ABT-493: Phase IIb data

Data from 74 treatment-naive or pegylated interferon treatment-experienced, non-cirrhotic patients with HCV genotype 2 infection in the open-label, international Phase IIb SURVEYOR-II trial showed that once-daily oral 300 mg ABT-493 plus 120 mg ABT-530 for 12 weeks led to an SVR 12 weeks after the end of treatment in 96% of patients. SVR12 rates were 100% each for once-daily 200 mg ABT-493 plus 120 mg ABT-530 with and without ribavirin for 12 weeks. In 121 treatment-naive or pegylated interferon treatment-experienced, non-cirrhotic patients with HCV genotype 3 infection, SVR12 rates were 93% for once-daily 300 mg ABT-493 plus 120 mg ABT-530 for 12 weeks; 93% for once-daily 200 mg ABT-493 plus 120 mg ABT-530 for 12 weeks; 94% for once-daily 200 mg ABT-493 plus 120 mg ABT-530 with ribavirin for 12 weeks; and 83% for once-daily 200 mg ABT-493 plus 40 mg ABT-530 for 12 weeks. Data were presented at the American Association for the Study of Liver Diseases meeting in San Francisco. ...